Shopping Cart
Remove All
  • TargetMol
    Your shopping cart is currently empty

Omecamtiv mecarbil

Copy Product Info
🥰Excellent
Catalog No. T2006Cas No. 873697-71-3
Alias CK-1827452

Omecamtiv mecarbil (CK-1827452) has been used in trials studying the treatment and basic science of Heart Failure, Echocardiogram, Pharmacokinetics, Chronic Heart Failure, and History of Chronic Heart Failure, among others.

Omecamtiv mecarbil

Omecamtiv mecarbil

Copy Product Info
🥰Excellent
Purity: 99.23%
Catalog No. T2006Alias CK-1827452Cas No. 873697-71-3
Omecamtiv mecarbil (CK-1827452) has been used in trials studying the treatment and basic science of Heart Failure, Echocardiogram, Pharmacokinetics, Chronic Heart Failure, and History of Chronic Heart Failure, among others.
Pack SizePriceUSA WarehouseGlobal WarehouseQuantity
1 mg$34In StockIn Stock
5 mg$77In StockIn Stock
10 mg$126In StockIn Stock
25 mg$207In StockIn Stock
50 mg$342In StockIn Stock
100 mg$496In StockIn Stock
1 mL x 10 mM (in DMSO)$68In StockIn Stock
Add to Cart
Add to Quotation
In Stock Estimated shipping dateUSA Warehouse[1-2 days] Global Warehouse[5-7 days]
All TargetMol products are for research purposes only and cannot be used for human consumption. We do not provide products or services to individuals. Please comply with the intended use and do not use TargetMol products for any other purpose.
Questions
TargetMol
View More

Batch Information

Select Batch
Purity:99.23%
Color:White
Contact us for more batch information

Resource Download

Product Introduction

Bioactivity
Description
Omecamtiv mecarbil (CK-1827452) has been used in trials studying the treatment and basic science of Heart Failure, Echocardiogram, Pharmacokinetics, Chronic Heart Failure, and History of Chronic Heart Failure, among others.
In vitro
Omecamtiv mecarbil induces a decrease in various hemodynamic parameters, including heart rate, mean left atrial pressure, and left ventricular end-diastolic pressure. The effects of Omecamtiv mecarbil on these hemodynamic parameters within dogs with left ventricular hypertrophy, while awake, show similar impacts without significant statistical differences. In conscious dogs with myocardial infarction (MI-sHF), Omecamtiv mecarbil significantly increases wall thickening (25%), stroke volume (44%), cardiac output (22%), and left ventricular (LV) contraction ejection time (26%).
In vivo
In isolated cardiomyocytes, Omecamtiv mecarbil (can) enhance(s) the contractility of myocytes, overcoming the inhibition of myosin by BDM without increasing calcium transients or inhibiting the PDE pathway. Ex-vivo, Omecamtiv mecarbil selectively activates cardiac myosin by increasing the rate of myosin ATPase, thereby enhancing myocardial contractility.
Kinase Assay
Axl Kinase activity assay: Test compounds are diluted to desired concentrations in kinase reaction buffer (50 mM HEPES pH 7.5, 10 mM MgCl2, 1 mM EGTA, 2 mM DTT, and 0.01% v/v Tween-20) and are briefly incubated with Axl kinase. The Axl kinase used is recombinant human Axl kinase (catalytic domain, amino acids 473-894) with a histidine tag. The reaction is initiated by the addition of ATP and fluorescein-labeled poly-GT substrate (poly Glu:Tyr, 4:1 polymer). Concentration of the various components in the assay (10 μL reaction volume) are: 1% DMSO, 93 ng/mL Axl kinase, 20 μM ATP, and 200 nM fluorescein poly-GT substrate. Following addition of ATP and fluorescein poly-GT substrate, incubation is for 60 min at room temperature, the enzyme reaction is stopped by addition of 10 μL terbium-labeled anti-phosphotyrosine PY20 antibody in EDTA-containing buffer. Final concentration of EDTA and antibody after addition to the reaction is 10 mM and 2 nM, respectively. The terbium conjugated antibody generates a time-resolved FRET signal with the fluorescein molecule (bound to the poly-GT substrate) when the substrate is phosphorylated. After one hour incubation at room temperature, fluorescence is measured with excitation of 320 nm and dual emission of 495 and 520 nm on an EnVision microplate reader. Signal is expressed in -636996terms of a TR-FRET ratio (fluorescence intensity at 520 nm to 495 nm).
SynonymsCK-1827452
Chemical Properties
Molecular Weight401.43
FormulaC20H24FN5O3
Cas No.873697-71-3
SmilesCOC(=O)N1CCN(Cc2cccc(NC(=O)Nc3ccc(C)nc3)c2F)CC1
Relative Density.1.344 g/cm3
Storage & Solubility Information
StorageIn solvent: -80°C for 1 year | Shipping with blue ice/Shipping at ambient temperature.
Solubility Information
Ethanol: 6 mg/mL (14.95 mM), Sonication is recommended.
DMSO: 74 mg/mL (184.34 mM), Sonication is recommended.
In Vivo Formulation
10% DMSO+40% PEG300+5% Tween 80+45% Saline: 2 mg/mL (4.98 mM), Sonication is recommended.
Please add the solvents sequentially, clarifying the solution as much as possible before adding the next one. Dissolve by heating and/or sonication if necessary. Working solution is recommended to be prepared and used immediately. The formulation provided above is for reference purposes only. In vivo formulations may vary and should be modified based on specific experimental conditions.
Solution Preparation Table
Ethanol/DMSO
1mg5mg10mg50mg
1 mM2.4911 mL12.4555 mL24.9109 mL124.5547 mL
5 mM0.4982 mL2.4911 mL4.9822 mL24.9109 mL
10 mM0.2491 mL1.2455 mL2.4911 mL12.4555 mL
DMSO
1mg5mg10mg50mg
20 mM0.1246 mL0.6228 mL1.2455 mL6.2277 mL
50 mM0.0498 mL0.2491 mL0.4982 mL2.4911 mL
100 mM0.0249 mL0.1246 mL0.2491 mL1.2455 mL

Calculator

  • Molarity Calculator
  • Dilution Calculator
  • Reconstitution Calculator
  • Molecular Weight Calculator

In Vivo Formulation Calculator (Clear solution)

Please enter your animal experiment information in the following box and click Calculate to obtain the stock solution preparation method and in vivo formula preparation method:
TargetMol | Animal experiments For example, if the intended dosage is 10 mg/kg for animals weighing 20 g , with a dosing volume of 100 μL per animal, TargetMol | Animal experiments and a total of 10 animals are to be administered, using a formulation of TargetMol | reagent 10% DMSO+ 40% PEG300+ 5% Tween 80+ 45% Saline/PBS/ddH2O , the resulting working solution concentration would be 2 mg/mL.
Stock Solution Preparation:

Dissolve 2 mg of the compound in 100 μL DMSOTargetMol | reagent to obtain a stock solution at a concentration of 20 mg/mL . If the required concentration exceeds the compound's known solubility, please contact us for technical support before proceeding.

Preparation of the In Vivo Formulation:

1) Add 100 μL of the DMSOTargetMol | reagent stock solution to 400 μL PEG300TargetMol | reagent and mix thoroughly until the solution becomes clear.

2) Add 50 μL Tween 80 and mix well until fully clarified.

3) Add 450 μL Saline,PBS or ddH2OTargetMol | reagent and mix thoroughly until a homogeneous solution is obtained.

This example is provided solely to demonstrate the use of the In Vivo Formulation Calculator and does not constitute a recommended formulation for any specific compound. Please select an appropriate dissolution and formulation strategy based on your experimental model and route of administration.
All co-solvents required for this protocol, includingDMSO, PEG300/PEG400, Tween 80, SBE-β-CD, and Corn oil, are available for purchase on the TargetMol website.
1 Enter information below:
mg/kg
g
μL
2 Enter the in vivo formulation:
% DMSO
%
% Tween 80
% Saline/PBS/ddH2O

Dose Conversion

You can also refer to dose conversion for different animals. More Dose Conversion

Tech Support

Please see Inhibitor Handling Instructions for more frequently ask questions. Topics include: how to prepare stock solutions, how to store products, and cautions on cell-based assays & animal experiments, etc

Keywords

Related Tags: buy Omecamtiv mecarbil | purchase Omecamtiv mecarbil | Omecamtiv mecarbil cost | order Omecamtiv mecarbil | Omecamtiv mecarbil chemical structure | Omecamtiv mecarbil in vivo | Omecamtiv mecarbil in vitro | Omecamtiv mecarbil formula | Omecamtiv mecarbil molecular weight